Is there a role for β-amyloid in depression?

Clinical Neuropsychiatry

Volumn 11, Issue 2, 2014, Pages 76-85

  Piccinni, Armando ^a   Veltri, Antonello ^a   Baroni, Stefano ^a   Marazziti, Donatella ^a   dell'Osso, Liliana ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Alzheimer's disease; Cognitive impairment; Depression; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN [1-40]; AMYLOID BETA PROTEIN [1-42]; BETA CATENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3BETA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN P53; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD LEVEL; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; HIPPOCAMPUS; HUMAN; LONG TERM POTENTIATION; MOOD DISORDER; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

EID: 84902198803     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Alley G.M., Bailey JA, Chen DM, et al. (2010). Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J Neurosci Res 88, 143-154.
2. Andersen K., Lolk A, Kragh-Sorensen P, Peterson NE, Green A. (2005). Depression and the risk of Alzheimer disease. Epidemiology 16, 233-38.
3. Andreasen N., Minthon L, Davidsson P et al. (2001). Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 349-50.
4. Arancibia S., Silhol M, Moulière F, et al. (2008). Protective effect of BDNF against beta-amyloid induced neurotoxicity in vitro and in vivo in rats. Neurobiol Disease 31, 316-326.
5. Arancio O., Chao MV. 2007. Neurotrophins, synaptic plasticity and dementia. Curr Op Neurobiol 17, 325-330.
6. Arvanitis D.N., Ducatenzeiler A, Ou JN, et al. (2007). High intracellular concentrations of amyloid-beta block nuclear translocation of phosphorylated CREB. J Neurochem 103, 216-228.
7. Aznar S., Knudsen GM (2011). Depression and Alzheimer's disease, is stress the initiating factor in a common neuropathological cascade? J Alzheimers Dis 23, 177-93.
8. Baba H., Nakano Y, Maeshima H, et al. (2012). Metabolism of amyloid-β protein may be affected in depression. J Clin Psychiatry 73, 1, 115-120.
9. Barnes D.E., Yaffe K, Byers AL, et al. (2012). Midlife vs latelife depressive symptoms and risk of dementia: differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry 69, 5, 493-498.
10. Baudry A., Mouillet-Richard S, Launay JM, Kellermann O (2011). New views on antidepressant action. Curr Opin Neurobiol 21, 6, 858-65.
11. Blasko I., Kemmler G, Jungwirth S, et al. (2010). Plasma Amyloid Beta-42 Independently Predicts Both Late-Onset Depression and Alzheimer Disease. Am J Geriatr Psychiatry 18, 973-82.
12. Bliss T.V., Richter-Levin G. (1993). Spatial learning and the saturation of long-term potentiation. Hippocampus 3, 123-5.
13. Bora E., Vahip S, Akdeniz F, et al. (2007). The effect of previous psychotic mood episodes on cognitive impairment in euthymic bipolar patients. Bipolar Disord 9, 468-77.
14. Bordji K., Becerril-Ortega J, Buisson A (2011). Synapses, NMDA receptor activity and neuronal Aβ production in Alzheimer's disease. Rev Neurosci 22, 3, 285-94.
15. Bordji K., Becerril-Ortega J, Nicole O, Buisson A (2010). Activation of extrasynaptic, but not synaptic, NMDA Receptors modifies Amyloid Precursor Protein expression pattern and increases amyloid-production. J Neurosci 30, 15927-15942.
16. Boyle L.L., Porsteinsson AP, Cui X, King DA, Lyness JM (2010). Depression predicts cognitive disorders in older primary care patients. J Clin Psychiatry 71, 74-79.
17. Bucciantini M., Giannoni E, Chiti F, et al. (2002). Inherent toxicity of aggregates implies a common mechanism for protein mis-folding diseases. Nature 416, 507-11.
18. Buckner R.L., Snyder AZ, Shannon BJ, et al. (2005). Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationalship between default activity, amyloid and memory. J Neurosci 25, 7709-7717.
19. Bulbena A., Berrios GE (1993). Cognitive function in the affective disorders: a prospective study. Psychopathology 26, 6-12.
20. Castrén E. (2004). Neurotrophic effects of antidepressant drugs. Curr Opin Pharmacol 4, 1, 58-64.
21. Chen Q.S., Wei WZ, Shimahara T, Xie CW (2002). Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem 77, 354-71.
22. Chuang D.M. (2005). The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 1053, 195-204.
23. Cirrito J.R., Kang JE, Lee J, et al. (2008). Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58, 42-51.
24. Cirrito J.R., Yamada KA, Finn MB, et al. (2005). Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913-922.
25. Colaianna M., Tucci P, Zotti M, et al. (2010). Soluble beta amyloid (1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state? Br J Pharmacol 159, 1704-15.
26. Cui X., Lyness JM, Tu X, King DA, Caine ED (2007). Does depression precede or follow executive dysfunction? Outcomes in older primary care patients. Am J Psychiatry 164, 1221-1228.
27. Cusi A.M., Macqueen GM, Spreng RN, McKinnon MC (2011). Altered empathic responding in major depressive disorder: relation to symptom severity, illness burden, and psychosocial outcome. Psychiatry Res 188, 231-236.
28. De Felice F, Velasco PT, Lambert MP, et al. (2007). Aβ oligomers induce neuronal oxidative stress through an NMDAR-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282, 11590-11601.
29. De Groot JC, de Leeuw FE, Oudkerk M, et al. (2000). Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 57, 1071-76.
30. Deane R., Bell RD, Sagare A, Zlokovic BV (2009). Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8, 16-30.
31. Deane R., Du Yan S, Submamaryan RK, et al. (2003). RAGE mediates amyloid-beta peptide transport across the bloodbrain barrier and accumulation in brain. Nat Med 9, 907-13.
32. Deane R., Wu Z, Sagare A, et al. (2004). LRP/amyloid betapeptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-44.
33. Deane R., Wu Z, Zlokovic BV (2004). RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35, 2628-31.
34. Decker H., Lo KY, Unger SM, Ferreira ST, Silcerman MA (2010). Amyloid-β peptide oligomers disrupt axonal transport through an NMDA receptor-dependent mechanism that is mediated by Glicogen Synthase Kinase 3β in primary cultured hippocampal neurons. J of Neurosci 30, 9166-9171.
35. Dell'Osso L, Del Debbio A, Veltri A, et al. (2010). Associations between Brain-Derived Neurotrophic Factor plasma levels and severity of the illness, recurrence and symptoms in depressed patients. Neuropsychobiology 62, 207-212.
36. Demuro A., Mina E, Kayed R, et al. (2005). Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280, 17294-300.
37. Devanand D.P., Sano M, Tang MX, et al. (1996). Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 53, 175-82.
38. Dickson D.W., Crystal HA, Bevona C, et al. (1995). Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16, 285-298.
39. Dotson V.M., Beydoun MA, Zonderman AB (2010). Recurrent depressive symptoms and the incidence of dementia and mild cognitive impairment. Neurology 75, 27-34.
40. Donahue J.E., Flaherty SL, Johanson CE, et al. (2006). RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112, 405-15.
41. Duman R.S. (2004). Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 5, 11-25.
42. Ferrier I.N., Stanton BR, Kelly TP, Scott J (1999). Neuropsychological function in euthymic patients with bipolar disorder. Br J Psychiatry 175, 246-251.
43. Fukumoto H., Tennis M, Locascio JJ, et al. (2003). Age but not diagnosis is the main predictor of plasma amyloid betaprotein levels. Arch Neurol 60, 958-964.
44. Geerlings M.I., den Heijer T, Koudstaal PJ, et al. (2008). History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 70, 1258-64.
45. Glahn D.C., Bearden CE, Barguil M et al. (2007). The neurocognitive signature of psychotic bipolar disorder. Biol Psychiatry 62, 910-16.
46. Gonzalo-Ruiz A, Gonzalez I, Sanz-Anquela JM (2003). Effects of b-amyloid protein on serotoninergic, noradrenergic, and cholinergic markers in neurons of the pontomesencephalic tegmentum in the rat. J Chemical Neuroanatomy 26, 153-169.
47. Gorwood P., Corruble E, Falissard B, Goodwin GM (2008). Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depressive disorder in a large sample of depressed outpatients. Am J Psychiatry 165, 731-739.
48. Graff-Radford NR, Crook JE, Lucas J, et al. (2007). Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 64, 354-362.
49. Green R.C., Cupples LA, Kurz A, et al. (2003). Depression as a risk factor for Alzheimer disease-The MIRAGE study. Arch Neurol 60, 753-9.
50. Gualtieri C.T., Johnson LG (2008). Age-related cognitive decline in patients with mood disorders. Progr Neuropsychopharmacol Biol Psychiatry 32, 962-967.
51. Gudmundsson P., Skoog I, Waern M, et al. (2007) The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry 15, 10, 832-838.
52. Gudmundsson P., Skoog I, Waern M, et al. (2010). Is there a CSF biomarker profile related to depression in elderly women? Psychiatry Res 176, 2-3, 174-178.
53. Gurol M.E., Irizarry MC, Smith EE, Raju S, et al. (2006). Plasma beta-amyloid and white mat ter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66, 23-29.
54. Hock C., Golombowski S, Müller-Spahn F, et al. (1998). Cerebrospinal fluid levels of amyloid precursor protein and amyloid beta-peptide in Alzheimer's disease and major depression-inverse correlation with dementia severity. Eur Neurol 39, 2, 111-118.
55. Hsieh H., Boehm J, Sato C, et al. (2006). AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52, 831-43.
56. Janus C., Pearson J, McLaurin J, et al. (2000). Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408, 979-982.
57. Jorm A.F., van Duijn CM, Chandra V, et al. (1991). Psychiatric history and related exposures as risk factors for Alzheimer' s disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20, 43-47.
58. Kagan B.L., Azimov R, Azimova R (2004). Amyloid peptide channels. J Membr Biol 202, 1-10.
59. Kayed R., Head E, Thompson JL, et al. (2003). Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-9.
60. Kessing L.V., Olsen EW, Mortensen PB, et al. (1999). Dementia in affective disorder: a case-register study. Acta Psichiatr Scand 100, 176-85.
61. Kessing L.V., Nilsson FM (2003). Increased risk of developing dementia in patients with major affective disorders compared to patients with other medical illnesses. J Affect Disord 73, 261-9.
62. Kessing L.V., Andersen PK (2004). Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 75, 1662-1666.
63. Kessing L.V., Søndergård L, Forman JL, Andersen PK (2008). Lithium treatment and risk of dementia. Arch Gen Psychiatry 65, 11, 1331-1335.
64. Kessing L.V., Forman JL, Andersen PK (2011). Do continued antidepressants protect against dementia in patients with severe depressive disorder? Int Clin Psychopharmacol 26, 6, 316-322.
65. Kim J.M., Kim SY, Bae KY, Kim SW, et al. (2010). Apolipoprotein e4 genotype and depressive symptoms as risk factors for dementia in an older Korean population. Psychiatry Investig 7, 135-140.
66. Kita Y., Baba H, Maeshima H, et al. (2009). Serum amyloid beta protein in young and elderly depression, a pilot study. Psychogeriatrics 9, 180-5.
67. Klyubin I., Walsh DM, Lemere Cal, et al. (2005). Amyloid-beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11, 556-561.
68. Koh S.H., Noh MY, Kim SH (2008). Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res 1188, 254-262.
69. Kohler S., van Boxtel MP, van Os J, et al. (2010). Depressive symptoms and cognitive decline in community-dwelling older adults. J Am Geriatr Soc 58, 5, 873-879
70. Korte M., Carroll P, Wolf E, et al. (1995). Hippocampal longterm potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc Natl Acad Sci USA 92, 8856-60.
71. Kramberger M.G., Jelic V, Kåreholt I, et al. (2012). Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease. Dement Geriatr Cogn Dis Extra 2, 1, 48-56.
72. Krishnan V., Nestler EJ (2008). The molecular neurobiology of depression. Nature 455, 894-902.
73. Kugaya A., Sanacora G (2005). Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr 10, 808-19.
74. Lambert M.P., Barlow AK, Chromy BA, et al. (1998). Diffusible, nonfibrillar ligands derived from Abeta 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95, 6448-53.
75. Lambert M.P., Barlow AK, Chromy BA, et al. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95, 6448-53.
76. Lesné S., Ali C, Gabriel C, et al. (2005). NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci 25, 9367-77.
77. Lesne S., Koh MT, Kotilinek L, Kayed R, et al. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-7.
78. Levine E.S., Crozier RA, Black IB, Plummer RM (1998). BDNF modulates hippocampal synaptic transmission by increasing NMDA receptor activity. Proc Natl Acad Sci USA 95, 10235-10239.
79. Longstreth W.T. Jr, Manolio TA, Arnold A, et al. (1996). Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people: the Cardiovascular Health Study. Stroke 27, 1274-82.
80. Lu Y., Christian K, Lu B (2008). BDNF: A key regulator for protein synthesis dependent LTP and long term memory. Neurobiol Learn Mem 89, 312-323.
81. Lue L.F., Kuo YM, Roher AE, et al. (1999). Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155, 853-862.
82. Machado-Vieira R, Manji HK, Zarate CA (2009). The role of tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 15, 525-539.
83. Malberg J.E., Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20, 24, 9104-10.
84. Manji H.K., Drevets WC, Charney DS (2001). The cellular neurobiology of depression. Nature Med 7, 541-547.
85. Marazziti D., Consoli G, Picchetti M, Carlini M, Faravelli L (2010). Cognitive impairment in major depression. Eur J Pharmacol 626, 83-6.
86. Martinez-Aran A, Vieta E, Reinares M, et al. (2004a). Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 161, 262-70.
87. Martinez-Aran A, Vieta E, Reinares M, et al. (2004b). Cognitive impairment in euthymic bipolar patients, implications for clinical and functional outcome. Bipolar Disorders 6, 224-32.
88. Marti{dotless}nez-Aran A, Torrent C, Tabares-Seisdedos R, et al. (2008). Neurocognitive impairment in bipolar patients with and without history of psychosis. J Clin Psychiatry 69, 233-39.
89. Martinez-Corla H, Green KN, Billings LM, et al. (2010). Memantine improves cognition and reduces Alzheimer'slike neuropathology in transgenic mice. AJP 176, 870-880.
90. Mattson M.P., Cheng B, Davis D, et al. (1992). Amyloid-beta peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12, 376-89.
91. Mawuenyega K.G., Sigurdson W, Ovod V, et al. (2010). Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330, 1774.
92. Mayeux R., Tang MX, Jacobs DM, et al. (1999). Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 46, 412-16.
93. Mayeux R., Honig LS, Tang MX, et al. (2003). Plasma A[ß]40 and A[ß]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61, 1185-1190.
94. McGrath J, Scheldt S, Welham J, Clair A (1997). Performance on tests sensitive to impaired executive ability in schizophrenia, mania and well controls: acute and subacute phases. Schizophrenia Research 26, 127-137.
95. McKay AP, Tarbuck AF, Shapleske J, et al. (1995). Neuropsychological function in manic depressive psychosis. Evidence for persistent deficits in patients with chronic, severe illness. British Journal of Psychiatry 167, 51-57.
96. McLean C A, Cherny RA, Fraser FW, et al. (1999). Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46, 860-866.
97. Metti A.L., Cauley JA, Newman AB, et al. (2012). Plasma Beta Amyloid Level and Depression in Older Adults. J Gerontol A Biol Sci Med Sci article in press.
98. Miles M.C., Tavares R, Johanson CE, et al. (2008). Hippocampus RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 1230, 273-80.
99. Morgan D., Diamond DM, Gottschall PE, et al. (2000). Abeta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985.
100. Okereke O.I., Xia W, Selkoe DJ, Grodstein F (2009). Ten-year change in plasma amyloid beta levels and late-life cognitive decline. Arch Neurol 66, 1247-53.
101. Origlia N., Bonadonna C, Rosellini A, et al. (2010). Microglial receptor for advanced glycation end product-dependent signal pathway drives beta-amyloid-induced synaptic depression and long-term depression impairment in entorhinal cortex. J Neurosci 30, 11414-25.
102. Origlia N., Capsoni S, Cattaneo A, et al. (2009). Abeta-dependent Inhibition of LTP in different intracortical circuits of the visual cortex: the role of RAGE. J Alzheimers Dis 17, 59-68
103. Origlia N., Righi M, Capsoni S, et al. (2008). Receptor for advanced glycation end product-dependent activation of p38 mitogen-activated protein kinase contributes to amyloid-beta-mediated cortical synaptic dysfunction. J Neurosci 28, 3521-30.
104. Osher Y., Dobron A, Belmaker RH, Bersudsky Y, Dwolatzky T (2011). Computerized testing of neurocognitive function in euthymic bipolar patients compared to those with mild cognitive impairment and cognitively healthy controls. Psychother Psychosom 80, 298-303.
105. Ownby R.L., Crocco E, Acevedo A, et al. (2006). Depression and risk for Alzheimer disease: systematic review, metaanalysis, and metaregression analysis. Arch Gen Psychiatry 63, 530-38.
106. Palop J.J., Mucke L (2010). Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 13, 812-8.
107. Parameshwaran K., Sims C, Kanju P, et al. (2007). Amyloid beta-peptide Abeta(1-42) but not Abeta(1-40) attenuates synaptic AMPA receptor function. Synapse 61, 367-74
108. Piccinni A., Del Debbio A, Medda P, et al. (2009). Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur Neuropsychopharmacol 19, 349-55.
109. Piccinni A., Marazziti D, Catena M, et al. (2008). Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 105, 279-283.
110. Piccinni A., Origlia N, Veltri A, et al. (2012). Plasma β-amyloid peptides levels: a pilot study in bipolar depressed patients. J Affect Disord 138, 1-2, 160-164.
111. Pomara N., Doraiswamy PM, Willoughby LM, et al. (2006). Elevation in plasma Abeta42 in geriatric depression: a pilot study. Neurochem Res 31, 341-349.
112. Pomara N., Bruno D, Sarreal AS, et al. (2012). Lower CSF Amyloid Beta Peptides and Higher F2-Isoprostanes in Cognitively Intact Elderly Individuals With Major Depressive Disorder. Am J Psychiatry 169, 5, 523-530.
113. Poo M.M. (2001). Neurotrophins as synaptic modulators. Nat Rev Neuroscience 2, 24-32.
114. Popoli M., Gennarelli M, Racagni G. Modulation of synaptic plasticity by stress and antidepressants. (2002). Bipolar Disord 4, 166-182.
115. Preda S., Govoni S, Lanni C, et al. (2008). Acute betaamyloid administration disrupts the cholinergic control of dopamine release in the nucleus accumbens. Neuropsychopharmacology 33, 1062-1070.
116. Qing H., He G, Ly PT, et al. (2008). Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 205, 2781-9.
117. Qiu W.Q., Sun X, Selkoe DJ, et al. (2007). Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly. Int J Geriatr Psychiatry 22, 536-342.
118. Rapp M.A., Schnaider-Beeri M, Grossman HT, et al. (2006). Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry 63, 161-67.
119. Ray B., Benerjee PK, Greig NH, Lahiri DK (2010). Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (AP) and amyloid beta (A beta) peptide in the human neuroblastoma cells. Neurosci Lett 470, 1-5.
120. Robinson L.J., Thompson JM, Gallagher P, et al. (2006). A metaanalysis of cognitive deficits in euthymic patients with bipolar disorder. J Affect Disord 93, 105-115.
121. Rosenberg P.B., Mielke MM, Xue QL, Carlson MC (2010). Depressive symptoms predict incident cognitive impairment in cognitive healthy older women. J Am Geriatr Soc 18, 204-211.
122. Saczynski J.S., Beiser A, Seshadri S, et al. (2010). Depressive symptoms and risk of dementia: the Framingham heart study. Neurology 75, 35-41.
123. Schröder J., Pantel J, Ida N, et al. (1997). Cerebral changes and cerebrospinal fluid beta-amyloid in Alzheimer's disease: a study with quantitative magnetic resonance imaging. Mol Psychiatry 2, 505-07.
124. Selkoe D.J. (1998). The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol 8, 447-453.
125. Selkoe D.J. (2001). Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimer Dis 3, 75-80.
126. Selkoe D.J. (2006). The ups and downs of Abeta. Nat Med 12, 758-59.
127. Selva G., Salazar J, Balanza-Martinez V, et al. (2007). Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning? J Psychiatr Res 41, 265-72.
128. Sen S., Duman R, Sanacora G (2008). Serum brain-derived neurotrophic factor, depression, and antidepressant medications: Meta-analyses and implications. Biol Psychiatry 64, 527-32.
129. Seppälä T.T., Herukka SK, Hänninen T, et al. (2010). Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study. J Neurol Neurosurg Psychiatry 81, 1123-7.
130. Shankar G.M., Bloodgood BL, Townsend M, Walsh DM, Selkoe D.J., Sabatini BL (2007). Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptordependent signaling pathway. J Neurosci 27, 2866-2875.
131. Shankar G.M., Li S, Mehta TH, et al. (2008). Soluble amyloidbeta protein dimers isolated directly from Alzheimer disease patients potently impair synaptic plasticity and memory. Nat Med 14, 837-842.
132. Shibata M., Yamada S, Kumar SR, et al. (2000). Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489-99.
133. Singh-Manoux A, Akbaraly TN, Marmot M, et al. (2010). Persistent depressive symptoms and cognitive function in late midlife: the Whitehall II study. J Clin Psychiatry 71, 1379-1385.
134. Steffens D.C., Plassman BL, Helms MJ, et al. (1997). A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer' s disease. Biol Psychiatry 41, 851-6.
135. Sun X., Mwamburi DM, Bungay K, et al. (2007). Depression, antidepressants, and plasma amyloid beta (beta) peptides in those elderly who do not have cardiovascular disease. Biol Psychiatry 62, 1413-1417.
136. Sun X., Steffens DC, Au R, et al. (2008). Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch Gen Psychiatry 65, 542-550.
137. Terry R.D., Masliah E, Salmon DP, et al. (1991). Physical basis of cognitive alterations in Alzheimer's disese: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30, 572-80.
138. Texidò L., Martin-Satuè M, Alberdi E, Solsona C, Matute C (2011). Amyloid β peptide oligomer directly activate NMDA receptors. Cell Calcium 49, 184-190.
139. Thambisetty M., Lovestone S (2010). Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med 4, 1, 65-79.
140. Tong L., Balazs R, Thornton PL, Cotman CW (2004). Betaamyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 24, 6799-6809.
141. Tong L., Thornton PL, Balazs R, Cotman CW (2001). Betaamyloid-(1-42) impairs activity-dependent cAMPresponse element-binding protein signaling in neurons at concentrations in which cell survival is not compromised. J Biol Chem; 276, 17301-17306.
142. Torres I.J., Boudreau VG, Yatham LN (2007). Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand 434, 17-26.
143. Townsend M., Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006). Effects of secreted oligomers of amyloid-beta protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572, 477-492.
144. Trabace L., Kendrick KM, Castrignano S, et al. (2007). Soluble amyloid beta1-42 reduces dopamine levels in rat prefrontal cortex: relationship to nitric oxide. Neuroscience 147, 652-663.
145. Tyszkiewicz J.P., Yan Z (2005). beta-Amyloid peptides impair PKC-dependent functions of metabotropic glutamate receptors in prefrontal cortical neurons. J Neurophysiol 93, 3102-11.
146. Van Dijk EJ, Prins ND, Vermeer SE, et al. (2004). Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55, 570-75.
147. Van Oijen M, Hofman A, Soares HD, et al. (2006). Plasma Abeta (1-40) and Abeta (1-42) and the risk of dementia: a prospective casecohort study. Lancet Neurol 5, 655-660.
148. Velakoulis D., Wood SJ, Wong MT, et al. (2006). Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 63, 139-49.
149. Vermeer S.E., Prins ND, den Heijer T, et al. (2003). Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348, 1215-22.
150. Waddington J.L., Brown K, O'Neill J, McKeon P, Kinsella A (1989). Cognitive impairment, clinical course and treatment history in out-patients with bipolar affective disorder: relationship to tardive dyskinesia. Psychol Med 19, 897-902.
151. Walsh D.M., Klyubin I, Fadeeva JV, et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
152. Walsh D.M., Klyubin I, Shankar GM, et al. 2005. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 33, 1087-90.
153. Walsh D.M., Townsend M, Podlisny MB, et al. (2005). Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue long-term potentiation. J Neurosci 25, 2455-62.
154. Walsh D.M., Selkoe DJ (2007). Abeta Oligomers-a decade of discovery. J Neurochem 101, 1172-84.
155. Wang H., Luo WJ, Zhang YW, et al. (2004). Presenilins and gamma-secretase inhibitors affect intracellular trafficking and cell surface localization of the gamma-secretase complex components. J Biol Chem 279, 40560-6.
156. Wang H.W., Pasternak JF, Kuo H, et al. (2002). Soluble oligomers of amyloid-beta (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924, 133-140.
157. Wang J., Dickson DW, Trojanowski JQ, Lee VM (1999). The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158, 328-337.
158. Whitlock J.R., Heynen AJ, Shuler MG, Bear MF (2006). Learning induces long-term potentiation in the hippocampus. Science 313, 1093-7.
159. Wilson R.S., Barnes LL, Mendes de Leon CF, et al. (2002). Depressive symptoms, cognitive decline, and risk of AD in older persons. Neurology 59, 364-70.
160. Wolfe J., Granholm E, Butters N, Saunders E, Janowsky D (1987). Verbal memory deficits associated with major affective disorders: a comparison of unipolar and bipolar patients. J Affect Disord 13, 83-92.
161. Xu W., Kawarabayashi T, Matsubara E, et al. (2008). Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res 1219, 169-179.
162. Yaffe K., Weston A, Graff-Radford NR, et al. (2011). Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 305, 261-6.
163. Yan S.D., Chen X, Fu J, et al. (1996). RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382, 685-91.
164. Yildiz-Yesiloglu A, Ankerst DP (2006). Neurochemical alterations of the brain in bipolar disorder and their implications for pathophysiology: a systematic review of the in vivo proton magnetic resonance spectroscopy findings. Prog Neuropsychopharmacol Biol Psychiatry 30, 969-95.
165. Zhang Y.W., Thompson R, Zhang H, Xu H (2011). APP processing in Alzheimer's disease. Mol Brain 4, 3.
166. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, et al. (2006). The cerebral beta-amyloid angiopathies: hereditary and sporadic. Brain Pathol 16, 30-39.
167. Zhao D., Watson JB, Xie CW (2004). Amyloid beta prevents activation of calcium/calmodulin-dependent protein kinase II and AMPA receptor phosphorylation during hippocampal long-term potentiation. J Neurophysiol 92, 5, 2853-8
168. Zubieta J.K., Huguelet P, O'Neil RL, Giordani BJ (2001). Cognitive function in euthymic Bipolar I Disorder. Psychiatry Res 102, 1, 9-20.